One-Year Comparative Effectiveness of Upadacitinib vs Tofacitinib for Ulcerative Colitis: A Multicenter Cohort Study.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 38470031.
- Also identified by DOI 10.14309/ajg.0000000000002746.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The comparative effectiveness of upadacitinib and tofacitinib for ulcerative colitis (UC) is poorly understood. In this retrospective cohort study, we compared steroid-free clinical remission (SFCR) and endoscopic response/remission at 52 weeks among adults initiating upadacitinib or tofacitinib for UC. A total of 155 patients initiated upadacitinib (n = 81; 30% prior tofacitinib exposure) or tofacitinib (n = 74; 0% prior upadacitinib exposure). After inverse probability of treatment-weighted logistic regression, upadacitinib was associated with significantly higher odds of SFCR (odds ratio 3.01, 95% confidence interval 1.39-6.55) vs tofacitinib. There were no differences for endoscopic response/remission. Upadacitinib was more effective at achieving SFCR in UC at 52 weeks vs tofacitinib.